C4 Therapeutics Inc (NASDAQ: CCCC) on Monday, plunged -6.22% from the previous trading day, before settling in for the closing price of $2.25. Within the past 52 weeks, CCCC’s price has moved between $1.09 and $7.14.
A company in the Healthcare sector has dropped its sales by -8.92% annually for the last half of the decade. The company achieved an average annual earnings per share of -2.80%. With a float of $59.98 million, this company’s outstanding shares have now reached $71.01 million.
C4 Therapeutics Inc (CCCC) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of C4 Therapeutics Inc is 15.73%, while institutional ownership is 65.80%. The most recent insider transaction that took place on Feb 18 ’25, was worth 2,107. In this transaction Chief Business Officer of this company sold 669 shares at a rate of $3.15, taking the stock ownership to the 107,805 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Business Officer sold 490 for $3.15, making the entire transaction worth $1,544. This insider now owns 110,842 shares in total.
C4 Therapeutics Inc (CCCC) Latest Financial update
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported -0.35 earnings per share (EPS) for the period falling under the consensus outlook (set at -0.33) by -0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.4 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.80% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.27% during the next five years compared to -8.92% drop over the previous five years of trading.
C4 Therapeutics Inc (NASDAQ: CCCC) Trading Performance Indicators
C4 Therapeutics Inc (CCCC) is currently performing well based on its current performance indicators. A quick ratio of 5.06 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.58, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.75 in one year’s time.
